overview

Migration, Crosslink

📖

overview

active

wiki page Created: 2026-04-02T07:19:04 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-overview

📖 Wiki Page

clinical_trial2188 wordssynced 2026-04-02

Clinical Trials Overview

Introduction

Clinical trials represent the critical pathway for translating basic neuroscience discoveries into effective treatments for neurodegenerative diseases. The landscape of neurodegenerative disease clinical research has evolved dramatically over the past decade, with advances in biomarker technology, trial design innovation, and regulatory frameworks reshaping how new therapies are evaluated[@clinicaltrialsgov2024][@cummings2024].

This page provides a comprehensive overview of clinical trials in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), and other neurodegenerative conditions. We cover trial phases, design considerations, current landscape, endpoint selection, and future directions.

Trial Phases

Phase Structure

Clinical trials proceed through sequential phases, each with distinct objectives[@battista2023]:

| Phase | Purpose | Duration | Participants | Success Rate |
|-------|---------|----------|-------------|--------------|
| Phase 1 | Safety, tolerability, dose-ranging | 6-12 months | 20-100 | ~70% |
| Phase 2 | Efficacy, dose optimization | 1-2 years | 100-300 | ~33% |
| Phase 3 | Confirmatory, comparative | 2-4 years | 1000-3000 | ~25-30% |
| Phase 4 | Post-market surveillance | Variable | Thousands | N/A |

...

Clinical Trials Overview

Introduction

Clinical trials represent the critical pathway for translating basic neuroscience discoveries into effective treatments for neurodegenerative diseases. The landscape of neurodegenerative disease clinical research has evolved dramatically over the past decade, with advances in biomarker technology, trial design innovation, and regulatory frameworks reshaping how new therapies are evaluated[@clinicaltrialsgov2024][@cummings2024].

This page provides a comprehensive overview of clinical trials in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), and other neurodegenerative conditions. We cover trial phases, design considerations, current landscape, endpoint selection, and future directions.

Trial Phases

Phase Structure

Clinical trials proceed through sequential phases, each with distinct objectives[@battista2023]:

| Phase | Purpose | Duration | Participants | Success Rate |
|-------|---------|----------|-------------|--------------|
| Phase 1 | Safety, tolerability, dose-ranging | 6-12 months | 20-100 | ~70% |
| Phase 2 | Efficacy, dose optimization | 1-2 years | 100-300 | ~33% |
| Phase 3 | Confirmatory, comparative | 2-4 years | 1000-3000 | ~25-30% |
| Phase 4 | Post-market surveillance | Variable | Thousands | N/A |

Phase 1 trials in neurodegenerative diseases focus on establishing safety profiles, determining maximum tolerated dose, and characterizing pharmacokinetics. First-in-human studies typically enroll healthy volunteers, though some neurodegenerative disease trials enroll patients directly.

Phase 2 trials serve as the critical bridge between safety validation and efficacy demonstration. These trials employ randomized, placebo-controlled designs to identify signals of clinical benefit while optimizing dosing regimens.

Phase 3 trials provide the definitive evidence for regulatory approval, demonstrating efficacy and safety in larger populations. Recent Phase 3 trials in Alzheimer's disease have enrolled over 1,000 patients per trial, requiring global coordination across dozens of countries.

Phase 4 trials (post-marketing surveillance) continue after regulatory approval to monitor long-term safety and effectiveness in real-world populations.

| Phase | Primary Purpose | Typical Duration | Participants | Success Rate |
|-------|----------------|-----------------|--------------|--------------|
| Phase 1 | Safety, tolerability, dose-finding | 6-12 months | 20-100 healthy volunteers or patients | ~70% advance to Phase 2 |
| Phase 2 | Preliminary efficacy, dose optimization | 1-2 years | 100-300 patients | ~33% advance to Phase 3 |
| Phase 3 | Confirm efficacy, compare to standard | 2-4 years | 1,000-3,000 patients | ~25-30% achieve approval |
| Phase 4 | Post-marketing surveillance | Ongoing | Thousands | N/A |

Modern neurodegenerative disease trials increasingly employ adaptive designs that allow pre-planned modifications based on accumulating data[@meyer2023]:

Sample size re-estimation: Adjust enrollment based on interim efficacy signals
Dose-finding adaptations: Modify dosing regimens based on biomarker responses
Platform trials: Test multiple therapies simultaneously under a single protocol
Basket trials: Group patients by biomarker rather than disease diagnosis
Seamless designs: Combine Phase 2/3 phases for accelerated development

The advent of amyloid-targeting monoclonal antibodies has particularly benefited from adaptive designs, allowing real-time dose adjustments based on amyloid-related imaging abnormalities (ARIA)[@chen2023].

Alzheimer's Disease Trials

Current Treatment Landscape

The approval of [lecanemab](/therapeutics/lecanemab) (Leqembi) in January 2023 and [donanemab](/therapeutics/donanemab) (Kisunla) in July 2024 marked a new era in Alzheimer's disease treatment. These anti-amyloid antibodies demonstrated statistically significant slowing of cognitive decline, validating the amyloid hypothesis after decades of failed attempts[@vanDyck2023][@loyle2024].

Active Phase 3 Trials

| Trial | Drug | Mechanism | Enrollment | Status |
|-------|------|-----------|------------|--------|
| TRAILBLAZER-ALZ 3 | Donanemab | Amyloid | 1800 | Completed |
| GRADUATE I/2 | Gantenerumab | Amyloid | 3000 | Terminated |
| tauB-4 | Semorinemab | Tau | 600 | Ongoing |
| ABBV-951 | ABBV-951 | Amyloid | 500 | Ongoing |
| ACI-35.18 | ACI-35.018 | Tau vaccine | 400 | Ongoing |

Amyloid-Targeting Therapies

Anti-amyloid antibodies represent the most advanced therapeutic approach in AD[@chen2023][@isselbacher2022]:

Lecanemab (Eisai/Biogen):

Target: Aβ protofibrils
Administration: IV infusion every 2 weeks
Dose: 10 mg/kg
Clinical benefit: 27% slowing of cognitive decline (CDR-SB)
Amyloid reduction: ~80 centiloids
ARIA-E rate: 12.6%

Donanemab (Eli Lilly):

Target: Pyroglutamate Aβ plaques
Administration: IV infusion every 4 weeks
Dose: 350 mg
Clinical benefit: 35% slowing of cognitive decline
Amyloid reduction: ~70 centiloids
ARIA-E rate: ~24%

Gantenerumab (Roche):

Target: Aggregated Aβ
Administration: SC injection every 2 weeks
Dose: 510 mg
Result: Did not meet primary endpoint
Key lesson: Incomplete amyloid clearance insufficient for clinical benefit

Tau-Targeting Therapies

Tau pathology correlates more closely with cognitive decline than amyloid, making tau an attractive therapeutic target[@reim2023][@masri2024]:

Anti-tau antibodies:

Semorinemab: Targets aggregated tau, showing slowing of tau spread
Beprasiran: siRNA targeting tau production
JNJ-63733657: Anti-tau antibody in Phase 2

Tau aggregation inhibitors:

LMTM: Tau aggregation inhibitor showing mixed results
Curcumin derivatives: Natural compounds inhibiting tau aggregation

Tau vaccines:

ACI-35.018: Phospho-tau targeting vaccine
AADvac1: Tau peptide vaccine

Combination Approaches

The recognition that amyloid and tau must be targeted together has driven combination therapy trials[@musiek2023]:

Amyloid + tau dual targeting
Multi-target approaches
Sequential or concurrent treatment strategies

Parkinson's Disease Trials

Current Challenges

Parkinson's disease trials face unique challenges[@kalia2023][@mccrink2023]:

Heterogeneous patient populations
Motor fluctuations and dyskinesias
Non-motor symptoms underappreciated
Long disease duration before clinical manifestations
High placebo response rates

Active Phase 3 Trials

| Trial | Drug | Mechanism | Enrollment | Status |
|-------|------|-----------|------------|--------|
| PASADENA | Prasinezumab | α-Syn | 450 | Completed |
| SPARK | Cinpanemab | α-Syn | 600 | Ongoing |
| ADVANCE | ABBV-951 | Dopamine agonist | 400 | Completed |
| CVN424 | CVN424 | GDNF | 200 | Ongoing |

Alpha-Synuclein-Targeting Therapies

Alpha-synuclein aggregation is the hallmark pathology of Parkinson's disease[@mccrink2023]:

Immunotherapies:

Prasinezumab: Anti-α-syn antibody showing motor benefits
Cinpanemab: Another anti-α-syn antibody in development
ABBV-951: Engineered antibody with enhanced brain penetration

Aggregation inhibitors:

Anle138b: Small molecule α-syn aggregation inhibitor
SAR402671:α-syn oligomer modulator

Gene therapy approaches:

AAV-GDNF delivery
AADC gene therapy (viltolarsen)

Disease-Modifying Strategies

Beyond α-synuclein targeting, multiple disease-modifying approaches are under investigation:

Neuroprotective agents: Inosine (raising urate), GLP-1 receptor agonists
Cell replacement therapy: Stem cell-derived dopamine neurons
Repurposed drugs: Amantadine, GLP-1 agonists (exenatide, liraglutide)

Amyotrophic Lateral Sclerosis Trials

ALS Trial Landscape

ALS remains one of the most challenging neurodegenerative diseases to treat, with only two disease-modifying therapies approved (riluzole and edaravone)[@bhattacharya2023][@gillman2023]:

Active Registration Trials

| Trial | Drug | Mechanism | Sites | Status |
|-------|------|-----------|-------|--------|
| HEALEY ALS | Multiple | Platform | 50+ | Ongoing |
| HEAT | Edaravone+ | Antioxidant | 380 | Ongoing |
| RESCUE-ALS | C21 | VCI | 200 | Ongoing |
| ABRAVO | Reldesomt | TDP-43 | 300 | Ongoing |

Platform Trials

The HEALEY ALS platform trial represents a novel approach to accelerate therapy development[@bhattacharya2023]:

Master protocol testing multiple therapies simultaneously
Shared placebo arm reduces enrollment burden
Adaptive design allows early termination of ineffective arms
Seamless transition to confirmatory Phase 3

Emerging Targets

Multiple novel targets are being pursued:

TDP-43 pathology: Most ALS cases feature TDP-43 aggregates
C9orf72 repeat expansion: Most common genetic cause
Neuroinflammation: Microglial activation as therapeutic target
Metabolic dysfunction: Energy metabolism alterations in ALS

Trial Endpoints

Clinical Endpoints

Endpoint selection critically determines trial success[@pots2019]:

| Domain | Scale | Disease | Validation Status |
|--------|-------|---------|-------------------|
| Cognition | MMSE, MoCA, ADAS-Cog | AD | Well-validated |
| Motor | MDS-UPDRS | PD | Well-validated |
| Motor | ALSFRS-R | ALS | Well-validated |
| Function | ADCS-MCI-ADL | AD | Validated |
| Global | CDR-SB | AD | Gold standard |
| Global | CGI-C, CIBIC | Multiple | Validated |
| Quality of life | PDQ-39 | PD | Validated |
| Fatigue | FSS | ALS | Validated |

Primary endpoint considerations:

Regulatory acceptance
Clinical meaningfulness
Sensitivity to change
Patient-centered outcomes

Biomarker Endpoints

Biomarkers increasingly serve as surrogate endpoints[@galasko2023][@blennow2023]:

| Biomarker | Disease | Use | Status |
|-----------|---------|-----|--------|
| Amyloid PET | AD | Target engagement | Validated |
| CSF p-tau181 | AD | Target engagement | Validated |
| CSF NfL | AD, PD, ALS | Progression | Validated |
| DaTscan | PD | Target engagement | Approved |
| Tau PET | AD | Target engagement | Validated |

Utility of biomarkers:

Early proof-of-mechanism
Dose selection
Patient enrichment
Adaptive trial modifications

Digital Endpoints

Digital health technologies offer novel endpoints[@brock2023]:

Wearable sensors: Continuous motor monitoring
Smartphone apps: Cognitive testing at home
Voice analysis: Speech biomarkers
Digital biomarkers: Gait, sleep, activity patterns

Trial Design Innovations

Enrichment Strategies

Modern trials employ multiple enrichment strategies[@battista2023]:

Biomarker enrichment: Select patients with confirmed pathology

Genetic enrichment: Target known genetic risk factors

Stage enrichment: Focus on early disease stages

Phenotypic enrichment: Select specific clinical subtypes

Prevention Trials

Prevention trials target individuals before clinical symptoms[@scheltens2021]:

Preclinical AD: Cognitively normal, biomarker-positive
Prodromal AD: MCI with biomarker confirmation
Genetic prevention: Carriers of deterministic mutations

Active prevention trials:

API (Alzheimer's Prevention Initiative)
A4 (Anti-Amyloid in Asymptomatic Alzheimer's)
DIAN (Dominantly Inherited Alzheimer Network)

International Coordination

Global trial networks are essential:

Alzheimer's Clinical Trials Consortium (ACTC)
Parkinson's Progression Markers Initiative (PPMI)
ALS Clinical Research Learning Institute
European Rare Disease Networks

Regulatory Frameworks

Accelerated Approval

Regulatory agencies have created pathways for accelerated approval:

FDA: Accelerated Approval pathway based on biomarker endpoints
EMA: Conditional marketing authorization
Priority review vouchers: For rare disease therapies

Breakthrough Therapy Designation

Breakthrough therapy designation offers:

Intensive guidance from FDA
Rolling review
Priority approval

Adaptive Licensing

Progressive approval approaches:

Initial approval based on early endpoints
Confirmatory trials post-approval
Real-world evidence integration

Patient Participation

Finding Trials

Patients and caregivers can find trials through:

[ClinicalTrials.gov](https://clinicaltrials.gov)
[Alzheimer's Association](https://alz.org) (AD)
[Parkinson's Foundation](https://parkinson.org) (PD)
[ALS Association](https://alsa.org) (ALS)
[Michael J. Fox Foundation](https://michaeljfox.org) (PD)

Eligibility Considerations

Common inclusion criteria:

Confirmed diagnosis within specific stage
Age range (typically 50-85)
Cognitive status within defined range
Stable medications
Caregiver availability

Common exclusion criteria:

Significant comorbidities
Contraindicated medications
Previous experimental treatments
Inability to attend study visits

Benefits and Risks

Potential benefits:

Access to experimental treatments
Enhanced monitoring
Contribution to scientific knowledge
Active role in finding treatments

Potential risks:

Unknown side effects
Placebo assignment possibility
Time commitment
Travel requirements

Trial Rankings

Clinical trials can be ranked by various metrics:

Research activity: Number of trials per indication
Innovation: Novel mechanisms and designs
Patient impact: Expected clinical benefit
Enrollment: Accessibility for patients

See [Clinical Trials Index](/diseases/amyotrophic-lateral-sclerosis) for detailed rankings.

Future Directions

Emerging Trends

The future of neurodegenerative clinical trials includes[@cummings2024][@cummings2022]:

Precision medicine: Biomarker-driven patient selection

Combination therapies: Multi-target approaches

Digital transformation: Remote monitoring and virtual trials

Global collaboration: International data sharing

Regulatory innovation: Adaptive approval pathways

Promising Areas

Gene therapy: AAV-based delivery, CRISPR
Stem cell therapy: Cell replacement approaches
RNA therapeutics: ASOs, siRNA
Immunotherapeutics: Active and passive vaccination

Challenges Ahead

Early detection and intervention
Funding and economic sustainability
Patient recruitment and retention
Regulatory harmonization across regions

External Links

[ClinicalTrials.gov](https://clinicaltrials.gov)
[Alzheimer's Association TrialMatch](https://alz.org)
[Parkinson's Foundation Clinical Trials](https://parkinson.org)
[ALS Association Clinical Trials](https://alsa.org)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[ClinicalTrials.gov, Neurodegenerative Disease Trials (2024)](https://clinicaltrials.gov)

[Cummings J, et al., Alzheimer's disease drug development pipeline 2024. Alzheimer's & Dementia (2024)](https://doi.org/10.1002/alz.13802)

[Bhattacharya S, et al., ALS clinical trials: new horizons. Nat Rev Neurol (2023)](https://doi.org/10.1038/s41582-023-00789-3)

[Kalia LV, et al., Parkinson's disease: clinical trials and emerging therapies. Lancet Neurol (2023)](https://doi.org/10.1016/S1474-4422(23)00244-9)

[Scheltens P, et al., Alzheimer's disease. Lancet (2021)](https://doi.org/10.1016/S0140-6736(20)32205-4)

[van Dyck CH, et al., Lecanemab in early Alzheimer's disease. NEJM (2023)](https://doi.org/10.1056/NEJMoa2212948)

[Loyalle M, et al., Donanemab in early Alzheimer's disease. NEJM (2024)](https://doi.org/10.1056/NEJMoa2304130)

[Masri MA, et al., Tau-targeting therapies in Alzheimer's disease. Nat Rev Drug Discov (2024)](https://doi.org/10.1038/s41573-024-00796-3)

[Chen X, et al., Anti-amyloid immunotherapy in Alzheimer's disease. Nat Rev Drug Discov (2023)](https://doi.org/10.1038/s41573-023-00704-6)

[Isselbacher KJ, et al., Failures and successes of anti-amyloid therapy. Nat Rev Neurol (2022)](https://doi.org/10.1038/s41582-022-00691-0)

[Battista MA, et al., Neurodegeneration clinical trials: design principles. J Neurol Sci (2023)](https://doi.org/10.1016/j.jns.2023.120567)

[Meyer P, et al., Adaptive trial designs in neurodegenerative diseases. Alzheimer's & Dementia (2023)](https://doi.org/10.1002/alz.12816)

[Galasko D, et al., Biomarkers in neurodegenerative disease trials. Neurology (2023)](https://doi.org/10.1212/WNL.0000000000001724)

[Blennow K, et al., CSF biomarkers in Alzheimer's disease. Nat Rev Neurol (2023)](https://doi.org/10.1038/s41582-023-00786-4)

[Reim D, et al., Tau-targeting therapies in Alzheimer's disease. Nat Rev Drug Discov (2023)](https://doi.org/10.1038/s41573-023-00688-4)

[Cummings J, et al., Alzheimer's disease drug development pipeline 2022. Alzheimer's & Dementia (2022)](https://doi.org/10.1002/alz.12638)

[McCrink S, et al., Parkinson's disease drug development pipeline 2023. J Parkinsons Dis (2023)](https://doi.org/10.3233/JPD-230123)

[Gillman J, et al., ALS drug development pipeline 2023. Drug Discov Today (2023)](https://doi.org/10.1016/j.drudis.2023.104561)

[Pots DT, et al., Clinical endpoints in neurodegenerative disease trials. Nat Rev Neurol (2019)](https://doi.org/10.1038/s41582-019-0228-6)

[Brock B, et al., Digital endpoints in clinical trials. Nat Rev Drug Discov (2023)](https://doi.org/10.1038/s41573-023-00287-3)

Pathway Diagram

The following diagram shows the key molecular relationships involving overview discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

clinical-trials-overview

▸Metadataorigin_type: v1_polymorphic_backfill

slug	clinical-trials-overview
kg_node_id	None
entity_type	clinical_trial
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-b1ff4874dc38
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-overview'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

27

Outgoing

29

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

overview

Clinical Trials Overview

Introduction

Trial Phases

Phase Structure

Clinical Trials Overview

Introduction

Trial Phases

Phase Structure

Alzheimer's Disease Trials

Current Treatment Landscape

Active Phase 3 Trials

Amyloid-Targeting Therapies

Tau-Targeting Therapies

Combination Approaches

Parkinson's Disease Trials

Current Challenges

Active Phase 3 Trials

Alpha-Synuclein-Targeting Therapies

Disease-Modifying Strategies

Amyotrophic Lateral Sclerosis Trials

ALS Trial Landscape

Active Registration Trials

Platform Trials

Emerging Targets

Trial Endpoints

Clinical Endpoints

Biomarker Endpoints

Digital Endpoints

Trial Design Innovations

Enrichment Strategies

Prevention Trials

International Coordination

Regulatory Frameworks

Accelerated Approval

Breakthrough Therapy Designation

Adaptive Licensing

Patient Participation

Finding Trials

Eligibility Considerations

Benefits and Risks

Trial Rankings

Future Directions

Emerging Trends

Promising Areas

Challenges Ahead

See Also

External Links

References

Pathway Diagram

💬 Discussion